Antiphospholipid Syndrome: Role of Antiphospholipid Antibodies in Neurology

Hematology/Oncology Clinics of North America

Volumn 22, Issue 1, 2008, Pages 95-105

  Dafer, Rima M ^a   Biller, José ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; CHLOROQUINE; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; GLYCOPROTEIN; GLYCOPROTEIN 1; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPAHTIDYLETHANOLAMINE ANTIBODY; PHOSPATHYLCHOLINE ANTIBODY; PHOSPATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ASHERSON SYNDROME; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; GENDER; HUMAN; NEUROLOGY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERMINAL DISEASE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADULT; ANTIPHOSPHOLIPID SYNDROME; HUMANS; ISCHEMIC ATTACK, TRANSIENT; RISK FACTORS; STROKE;

EID: 38149124837     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.10.005     Document Type: Review

References (72)

1. Gharavi A.E., Harris E.N., Asherson R.A., et al. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 46 1 (1987) 1-6
2. McNeil H.P., Chesterman C.N., and Krilis S.A. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 73 4 (1989) 506-513
3. Bevers E.M., Galli M., Barbui T., et al. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66 6 (1991) 629-632
4. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15 2 (2000) 145-151
5. Love P.E., and Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112 9 (1990) 682-698
6. Merkel P.A., Chang Y., Pierangeli S.S., et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101 6 (1996) 576-583
7. Janardhan V., Wolf P.A., Kase C.S., et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 35 3 (2004) 736-741
8. Carreras L.O., Forastiero R.R., and Martinuzzo M.E. Which are the best biological markers of the antiphospholipid syndrome?. J Autoimmun 15 2 (2000) 163-172
9. Galli M., Luciani D., Bertolini G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 5 (2003) 1827-1832
10. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 7 (1999) 1309-1311
11. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 2 (2006) 295-306
12. Brey R.L., Hart R.G., Sherman D.G., et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 40 8 (1990) 1190-1196
13. Blohorn A., Guegan-Massardier E., Triquenot A., et al. Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: a descriptive study of 139 patients. Cerebrovasc Dis 13 3 (2002) 156-162
14. Singh K., Gaiha M., Shome D.K., et al. The association of antiphospholipid antibodies with ischaemic stroke and myocardial infarction in young and their correlation: a preliminary study. J Assoc Physicians India 49 (2001) 527-529
15. Nagaraja D., Christopher R., and Manjari T. Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. J Neurol Sci 150 2 (1997) 137-142
16. Kushner M.J. Prospective study of anticardiolipin antibodies in stroke. Stroke 21 2 (1990) 295-298
17. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43 10 (1993) 2069-2073
18. Devilat M., Toso M., and Morales M. Childhood stroke associated with protein C or S deficiency and primary antiphospholipid syndrome. Pediatr Neurol 9 1 (1993) 67-70
19. Tuhrim S., Rand J.H., Wu X.X., et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 30 8 (1999) 1561-1565
20. Tuhrim S., Rand J.H., Wu X., et al. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 53 7 (1999) 1523-1527
21. Zielinska J., Ryglewicz D., Wierzchowska E., et al. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res 21 7 (1999) 653-657
22. Toschi V., Motta A., Castelli C., et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 29 9 (1998) 1759-1764
23. Levine S.R., Brey R.L., Joseph C.L., et al. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 23 2 Suppl (1992) I29-I32
24. Brey R.L., Abbott R.D., Curb J.D., et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 32 8 (2001) 1701-1706
25. Brey R.L., Stallworth C.L., McGlasson D.L., et al. Antiphospholipid antibodies and stroke in young women. Stroke 33 10 (2002) 2396-2400
26. Levine S.R., Brey R.L., Tilley B.C., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291 5 (2004) 576-584
27. Fustinoni O., and Biller J. Recurrent cerebral infarcts in antiphospholipid syndrome. In: Rabinstein A.A., and Wijdicks E.F.M. (Eds). Tough calls in acute neurology (2004), Elsevier, Philadelphia 199-215
28. Milstone A., Fan A., and Fuchs H. Antiphospholipid syndrome associated with seizures. South Med J 89 7 (1996) 738-740
29. Manna R., Ricci V., Curigliano V., et al. Psychiatric manifestations as a primary symptom in antiphospholipid syndrome. Int J Immunopathol Pharmacol 19 4 (2006) 915-917
30. Gomez-Puerta J.A., Cervera R., Calvo L.M., et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) 44 1 (2005) 95-99
31. Rafai M.A., Fadel H., Gam I., et al. [Recurrent stroke revealing catastrophic antiphospholipid syndrome with hepatitis C viral infection]. Rev Neurol (Paris) 162 11 (2006) 1131-1134 [in French]
32. Carter D., Olchovsky D., Yonath H., et al. Simultaneous deep vein thrombosis and transverse myelitis with negative serology as a first sign of antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol 25 5 (2006) 756-758
33. Besbas N., Anlar B., Apak A., et al. Optic neuropathy in primary antiphospholipid syndrome in childhood. J Child Neurol 16 9 (2001) 690-693
34. IJdo J.W., Conti-Kelly A.M., Greco P., et al. Antiphospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?. Lupus 8 2 (1999) 109-115
35. Garg N., Zivadinov R., Ramanathan M., et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 187 (2007) 159-165
36. Avcin T., Markelj G., Niksic V., et al. Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine. Cephalalgia 24 10 (2004) 831-837
37. Tietjen G.E. Migraine and antiphospholipid antibodies. Cephalalgia 12 2 (1992) 69-74
38. Nakos G., Tziakou E., Maneta-Peyret L., et al. Antiphospholipid antibodies in serum from patients with Guillain-Barre syndrome. Intensive Care Med 31 10 (2005) 1401-1408
39. Cavallasca J.A., Gutierrez D.M., Bercellini E.A., et al. Sudden sensorineural hearing loss as a manifestation of primary antiphospholipid syndrome. Joint Bone Spine 74 (2007) 403-404
40. Kang K.T., and Young Y.H. Sudden sensorineural hearing loss in a patient with primary antiphospholipid syndrome. J Laryngol Otol (2007) 1-3
41. Wiles N.M., Hunt B.J., Callanan V., et al. Sudden sensorineural hearing loss and antiphospholipid syndrome. Haematologica 91 (2006) e124-e127
42. Chapman J., Rand J.H., Brey R.L., et al. Nonstroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 12 7 (2003) 514-517
43. Martino D., Chew N.K., Mir P., et al. Atypical movement disorders in antiphospholipid syndrome. Mov Disord 21 7 (2006) 944-949
44. Frances C., Niang S., Laffitte E., et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 52 6 (2005) 1785-1793
45. Turiel M., Sarzi-Puttini P., Peretti R., et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 96 4 (2005) 574-579
46. Asherson R.A. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 210 10 (2005) 727-733
47. Miesbach W., Asherson R.A., Cervera R., et al. The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmun Rev 6 2 (2006) 94-97
48. Bucciarelli S., Espinosa G., Cervera R., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54 8 (2006) 2568-2576
49. Bucciarelli S., Cervera R., Espinosa G., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 6 2 (2006) 72-75
50. Bayraktar U.D., Erkan D., Bucciarelli S., et al. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 34 2 (2007) 346-352
51. Csepany T., Bereczki D., Kollar J., et al. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 250 11 (2003) 1348-1354
52. Provenzale J.M., Heinz E.R., Ortel T.L., et al. Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings. Radiology 192 2 (1994) 531-537
53. Lim W., Crowther M.A., and Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295 9 (2006) 1050-1057
54. Erkan D., Harrison M.J., Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56 7 (2007) 2382-2391
55. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 15 (1995) 993-997
56. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 5 (2005) 848-853
57. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 12 (2003) 1133-1138
58. Derksen R.H., de Groot P.G., and Kappelle L.J. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology 61 1 (2003) 111-114
59. Wallace D.J. Antimalarial agents and lupus. Rheum Dis Clin North Am 20 1 (1994) 243-263
60. Espinola R.G., Pierangeli S.S., Gharavi A.E., et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87 3 (2002) 518-522
61. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314 7076 (1997) 253-257
62. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 11 (2004) 1222-1226
63. Glasnovic M., Bosnjak I., Vcev A., et al. Antibody profile of pregnant women with antiphospholipid syndrome and pregnancy outcome after treatment with low-dose aspirin and low-weight molecular heparin. Coll Antropol 31 1 (2007) 173-177
64. Branch D.W., Peaceman A.M., Druzin M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182 1 Pt 1 (2000) 122-127
65. Ruffatti A., Marson P., Pengo V., et al. Plasma exchange in the management of high-risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 6 3 (2007) 196-202
66. Uthman I., Shamseddine A., and Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 33 1 (2005) 11-17
67. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 6 2 (2006) 98-103
68. Cervera R., Asherson R.A., and Font J. Catastrophic antiphospholipid syndrome. Rheum Dis Clin North Am 32 3 (2006) 575-590
69. Rubenstein E., Arkfeld D.G., Metyas S., et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33 2 (2006) 355-357
70. Trappe R., Loew A., Thuss-Patience P., et al. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 85 2 (2006) 134-135
71. Merrill J.T. Rituximab in antiphospholipid syndrome. Curr Rheumatol Rep 5 5 (2003) 381-382
72. Tanne D., D'Olhaberriague L., Trivedi A.M., et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 21 2 (2002) 93-99